Cargando…
Midazolam Pharmacokinetics in Morbidly Obese Patients Following Semi-Simultaneous Oral and Intravenous Administration: A Comparison with Healthy Volunteers
BACKGROUND: While in vitro and animal studies have shown reduced cytochrome P450 (CYP) 3A activity due to obesity, clinical studies in (morbidly) obese patients are scarce. As CYP3A activity may influence both clearance and oral bioavailability in a distinct manner, in this study the pharmacokinetic...
Autores principales: | Brill, Margreke J. E., van Rongen, Anne, Houwink, Aletta P. I., Burggraaf, Jacobus, van Ramshorst, Bert, Wiezer, René J., van Dongen, Eric P. A., Knibbe, Catherijne A. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171595/ https://www.ncbi.nlm.nih.gov/pubmed/25141974 http://dx.doi.org/10.1007/s40262-014-0166-x |
Ejemplares similares
-
The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery
por: Brill, Margreke J., et al.
Publicado: (2015) -
Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults
por: van Rongen, Anne, et al.
Publicado: (2017) -
Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1‐OH‐midazolam in morbidly obese and weight loss surgery patients
por: Brill, MJE, et al.
Publicado: (2015) -
Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers
por: van Rongen, A, et al.
Publicado: (2015) -
Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen
por: van Rongen, Anne, et al.
Publicado: (2016)